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Abstract 
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease and identification of 
new therapeutic targets is needed. Nicotinamide phosphoribosyltransferase (NAMPT) is both an 
extracellular and intracellular protein. Circulating NAMPT is increased in diabetics and in chronic kidney 
disease patients. The role of NAMPT in renal cell biology is poorly understood. NAMPT mRNA and 
protein were increased in the kidneys of rats with streptozotocin-induced diabetes. Immunohistochemistry 
localized NAMPT to glomerular and tubular cells in diabetic rats. The inflammatory cytokine TNFα 
increased NAMPT mRNA, protein and NAD production in cultured kidney human tubular cells. 
Exogenous NAMPT increased the mRNA expression of chemokines MCP-1 and RANTES. The NAMPT 
enzymatic activity inhibitor FK866 prevented these effects. By contrast, FK866 boosted TNFα-induced 
expression of MCP-1 and RANTES mRNA and endogenous NAMPT targeting by siRNA also had a 
proinflammatory effect. Furthermore, FK866 promoted tubular cell apoptosis in an inflammatory milieu 
containing the cytokines TNFα/IFNγ. In an inflammatory environment FK866 promoted tubular cell 
expression of the lethal cytokine TRAIL. These data are consistent with a role of endogenous NAMPT 
activity as an adaptive, protective response to an inflammatory milieu that differs from the 
proinflammatory activity of exogenous NAMPT. Thus, disruption of endogenous NAMPT function in 
stressed cells promotes tubular cell death and chemokine expression. This information may be relevant 
for the design of novel therapeutic strategies in DN. 
 
Key words: diabetes, NAMPT, apoptosis, inflammation, kidney. 
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1. Introduction 
Diabetic end-organ damage contributes to at least 233,000 yearly deaths in the US alone. Diabetic 
nephropathy (DN) is the most common cause of end-stage renal disease [1, 2]. Failure of current 
therapeutic approaches to successfully prevent progression of DN in a sizable proportion of patients must 
be ascribed to an incomplete understanding of the molecular pathways contributing to DN progression. 
The diabetic microenvironment induces apoptosis in various organs and apoptosis is believed to 
contribute to the gradual loss of renal function and renal cell mass in DN [3-5]. Renal tubular epithelial, 
endothelial and interstitial cell apoptosis is observed in DN[6-8]. DN is also characterized by an 
inflammatory response [9, 10]. Both apoptosis and inflammation may be interrelated. Thus several 
cytokines, such as TNFα and TRAIL regulate both apoptosis and inflammation in kidney cells in a 
diabetic milieu[10].  
Nicotinamide phosphoribosyltransferase (NAMPT)/visfatin/pre-B-cell colony-enhancing factor (PBEF) 
was originally identified as a secreted growth factor for early B cells [11]. Visfatin was described as an 
adipokine with insulin mimetic action that improved glucose tolerance [12]. However, the original 
description of visfatin activity was retracted because of the irreproducibility of the results. NAMPT was 
described as an intracellular enzyme in the mammalian salvage pathway of nicotinamide adenine 
dinucleotide (NAD)+ that catalyzes the synthesis of nicotinamide mononucleotide (NMN) from 
nicotinamide and phosphoribosylpyrophosphate (PRPP) [13]. NAMPT is now the official name for gene 
and protein approved by the HUGO Gene Nomenclature Committee [14, 15]. The NAMPT gene encodes 
a 491 amino acid protein with a predicted molecular weight of 52 kD. The crystal structure of NAMPT 
suggested a homodimeric enzyme [15]. Additional non-enzymatic NAMPT functions include 
proinflammatory effects on leukocytes and tumor cells [16, 17], pro-angiogenic effects on endothelial 
cells [18] and proliferative actions on vascular smooth muscle cells [19]. FK866 is now considered a 
competitive inhibitor of NAMPT enzymatic activity that reduces NAD+ levels and promotes apoptosis of 
tumor cells[15] [20]FK866 is now considered a competitive inhibitor of NAMPT enzymatic activity that 
reduces NAD+ levels and promotes apoptosis of tumor cells[15] [20]. In this regard, studies are underway 
to validate NAMPT as a target for the development of new anticancer agents. 
There is scarce information on NAMPT and kidney disease. High glucose increases NAMPT expression 
in cultured rat mesangial cells, and murine podocytes and tubular cells [21, 22]. Exogenous extracellular 
NAMPT increased the synthesis of pro-fibrotic molecules in these renal cell types through a mechanism 
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requiring actin polymerization and/or glucose uptake since it was inhibited by the actin polymerization 
inhibitor cytochalasin B. In a genetic rat model of type 2 diabetes, plasma NAMPT levels were increased 
in the early stages of DN and positively correlated with microalbuminuria. Glomerular and tubular cell 
NAMPT was increased in this model of DN. As a whole, these data suggested a deleterious action of 
NAMPT on renal cells that might contribute to the pathogenesis of DN [21, 22]. Mesangial cell NAMPT 
enzymatic activity may be inhibited by FK866 [21]. However the role of NAMPT enzymatic activity in 
renal cells beyond regulation of glucose uptake was not addressed. 
We now aimed at unraveling the role in kidney cells of the increased endogenous NAMPT observed 
during kidney injury. We describe increased local kidney NAMPT in a type 1 diabetes model and in 
cultured tubular cells exposed to TNFα. We also describe the interplay between endogenous NAMPT and 
inflammatory cytokines in the regulation of chemokine expression and cell death. The data suggest a 
cytoprotective, anti-inflammatory role of inflammation-induced endogenous NAMPT in tubular cells. 
 
2. Materials and methods 
2.1 Animal model 
Diabetes was induced in six 6-week-old rats (WKY, Criffa, Barcelona, Spain) by a single intraperitoneal 
injection of 50mg/Kg streptozotocin (Sigma, St. Louis, MO, USA) in 0.01 M citrate buffer pH 4.5. Six 
control rats received the vehicle. Rats were sacrificed at 6 weeks following induction of diabetes. Kidneys 
were perfused in situ with cold saline before removal. One kidney was fixed in buffered formalin, 
embedded in paraffin and used for immunohistochemistry, and the other kidney was snap-frozen in liquid 
nitrogen for RNA and protein studies of renal cortexes [23]. Insulin (Insulatard NPH, Novo Nordisk, 
Denmark) was administered at a dose of 1-4 IU s.c. weekly to prevent death from 7 days after 
administration of streptozotocin, once all animals had blood glucose levels >400 mg/dl. Twenty-four hour 
albuminuria was assessed by ELISA (Celltrend, Luckenwalde, Germany). Table 1 presents animal model 
data. All studies were performed in accordance with the European Union normative. 
2.2 Immunohistochemistry  
Immunohistochemistry was carried out in 5 m thick paraffin-embedded rat kidney sections. The primary 
antibody was a mouse monoclonal anti-NAMPT (1:200, Enzo life science). Sections were counterstained 
with Carazzi`s hematoxylin. Negative controls included incubation with a non-specific immunoglobulin 
of the same isotype as the primary antibody. Image quantification was carried out with ImageProPlus 
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software (MediaCybernetics, Bethesda, MD) as previously described [24]. This software allows selecting 
and calculating the area of pixels with similar color. Results are shown as percentage of positive stained 
area versus total area from 10 fields per kidney (x200 magnification). 
2.3 Cell culture 
HK-2 human proximal tubular epithelial cells (ATCC, Rockville, MD) were grown on RPMI 1640 
(GIBCO, Grand Island, NY), 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 
U/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL sodium 
selenite, and 5 ng/mL hydrocortisone in 5% CO2 at 37 C as previously described [10]. For experiments 
cells were rested in serum-free media for 24 h prior to the addition of stimuli and throughout the 
experiment. To assess the effect of different concentrations of glucose, cells were grown in DMEM 5 mM 
or 25 mM glucose (Lonza) with the same additives [25].  
2.4 Cell stimulation and NAMPT targeting. 
Exogenous extracelullarextracellular NAMPT (eNAMPT) was purchased from Enzo Lifesciences. The 
protein is produced in HEK3 cells and secreted using a proprietary signal peptide. The purity is ≥95% and 
the endotoxin content is < 0.1EU/ g protein (LAL-test). Concentrations used (10-200 ng/ml range) are 
indicated in the figure legends. Wild-type and mutant NAMPT (R392A, S200D and H247E) mutants (a 
kind gift from C.Wolberger) [26] were used at 100 ng/ml. R392A retains 36% of the original enzymatic 
activity showed by NAMPT, S200D 12% and H247E 8.50% . NAMPT siRNA (ID 10135;Trilencer-
27, SR306835 Origene). Cells were transfected with lipofectamine. FK866 (1-10nM; Axon 1279, 
AxonMedchem) was always added 90 minutes before other stimuli. 50 ng/ml of TNF  and 5 ng/ml of 
IFN  (Peprotech, UK) were used. 
2.5 NAD/NADH assay 
Total cell NAD was assayed by a commercial NAD/NADH quantification kit following manufacturer’s 
instructions (Abcam, Cambridge, UK). Briefly, cells were washed in cold PBS and lysed. Fifty 
microliters cell lysate were used for the kit protocol and for protein quantification. All results were 
corrected by the protein content of each sample. 
2.6 Cell death and apoptosis 
Apoptosis was quantified by flow cytometry of DNA content, as previously described [27]. Adherent 
cells were pooled with spontaneously detached cells and stained in 100 µg/mL propidium iodide, 0.05% 
NP-40, 10 µg/mL RNAse A in PBS at 4 C for >1 hour. This assay permeabilizes the cells and allows 
Con formato: Resaltar
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entry of propidium iodide in all cells, dead and alive. Nuclear fragmentation and the consequent reduction 
in DNA amount (hypodiploid cells) is one of the main characteristics of apoptotic cells. The percentage of 
apoptotic cells with decreased DNA content (A0) was counted. Exposure to a lethal cytokine cocktail (50 
ng/ml TNF , and 5 ng/ml IFN , Peprotech, UK) present in the diabetic milieu for 24h was used as a 
proinflammatory lethal stimulus[10]. Cytokine concentrations were based on prior experience and dose-
response studies from our lab [28, 29]. Cells were seeded at a density of 25,000/ml (12-well plates for 
flow cytometry and coverslips for cytofluorescence) and grown for 24 h. Thereafter, they were rested in 
serum-free medium for 24 h and stimuli were added to subconfluent cells. Cells were also seeded in 96-
well plates, serum depleted for 24 hours, stimulated and then assayed for cell viability with the MTS-
PMS assay (Promega). 
2.7 Western blot 
Proteins extracts were isolated with lysis buffer and western blots were performed as described previously 
[27]. Membranes were incubated overnight at 4ºC with anti-NAMPT antibody (1:2,000, EnzoLife 
Science), which recognizes the intracellular and extracellular forms of human NAMPT, anti-TRAIL 
(1:1,000, R&D systems), or mouse anti-β Actin monoclonal antibody (1:5,000, Abcam) followed by 
incubation with horseradish peroxidase-conjugated secondary antibody (1:2,000, Amersham, Aylesbury, 
UK). Blots were developed with the enhanced chemiluminescence method (ECL) following the 
manufacturer’s instructions (Amersham). 
2.8 Reverse transcription and real time PCR 
RNA was isolated using TRIzol reagent. Reverse transcription of RNA and real time quantitative-PCR 
was performed as previously described. Pre-developed TaqMan reagents were used for RANTES and 
MCP-1 (Applied Biosystems, Darmstadt, Germany), and normalized for 18S ribosomal RNA. 
Quantification of templates and relative expression for each gene was achieved following the model 
R=2e(-ΔΔCt). Serial dilutions of kidney or cellular cDNA were included in all PCR runs and served as 
standard curve. All measurements were performed in duplicate. Controls consisting of bidistilled H2O 
were negative in all runs. 
2.9 ELISA 
The ELISA kit for MCP-1 (R&D, Minneapolis, MN; USA) was carried out following manufacture's 
instructions in HK2 cell culture supernatants. Final wavelength was measured at 450nm and corrected by 
540 nm wavelength. 
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2.10 Statistical analysis 
Results are expressed as mean ± S.E.M. of at least three independent experiments. Significance at the p<0.05 
level was assessed by non-parametric Mann-Whitney test for two groups of data and Kruskal-Wallis or 
one-way analysis (ANOVA) with a Bonferroni post hoc correction for analysis of differences between 
three or more groups by SPSS software (SPSS Inc., Chicago, IL). 
 
3. Results 
3.1 Increased local kidney NAMPT in rat type I diabetes 
Rats with streptozotocin-induced diabetes or non-diabetic vehicle-injected controls were sacrificed at 6 
weeks. At the time of sacrifice, diabetic rats had developed albuminuria (Table 1). Whole kidney 
NAMPT protein (Fig. 1A) and mRNA (Fig. 1B) were increased in the diabetic kidney. 
Immunohistochemistry localized NAMPT expression to glomerular and tubular cells (Fig. 1C,D). 
3.2 TNFα increases NAMPT in cultured human tubular cells 
We focused on tubular cells in search of factors potentially driving NAMPT expression in DN. TNFα is a 
multifunctional cytokine involved in DN progression [9, 30]. TNFα increased NAMPT mRNA expression 
at three hours in cultured human tubular epithelial cells. There was a non-significant trend towards 
increased NAMPT mRNA levels in cells cultured with high glucose concentrations at 24 (Fig. 2A) and 48 
hours (data not shown). Similar results were observed at the protein level. High glucose tended to 
increase NAMPT while TNFα significantly increased cell-associated NAMPT expression after 48 hours 
of stimulation (Fig. 2B), while increased levels of soluble NAMPT were already evident at 24 and 48h 
following TNFα stimulation (Suppl Fig. 1). No differences in protein expression were observed at 3h 
(not shown). TNFα also increased NAD, suggesting an increased NAMPT enzymatic activity after 24 
hours of stimulation, an effect abrogated by the NAMPT enzymatic activity inhibitor FK866 (Fig. 2C). 
However, we cannot exclude that TNFα modulates nicotinamide nucleotide adenylyltransferase 
(NMNAT), the enzyme directly responsible for NAD generation. 
3.3 Exogenous NAMPT is proinflammatory in tubular cells 
In order to assess the role of NAMPT in tubular cells we added exogenous NAMPT to the cells. 
Exogenous NAMPT did not modulate human tubular cell viability (Fig. 3A), apoptosis (Fig. 3B) or 
proliferation (Fig. 3C). However, NAMPT dose-dependently increased the mRNA expression of the 
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chemokine MCP-1 (Fig. 4A). This effect is similar to that previously reported in murine tubular cells and 
podocytes and human vascular smooth muscle cells [22, 31]. 
3.4 Exogenous NAMPT proinflammatory activity depends on its enzymatic activity 
Previously described actions of exogenous NAMPT on kidney cells were thought to be a cytokine-like 
activity dependent on its now retracted insulin-mimetic properties promoting glucose entry into the cells 
[21, 32]. However, in cultured human tubular cells inhibition of NAMPT enzymatic activity by FK866 
decreased the proinflammatory actions of exogenous NAMPT on the mRNA expression of the 
chemokines MCP-1 (Fig. 4B) and RANTES (Fig. 4C). We confirmed the requirement for the enzymatic 
activity for the proinflammatory effects using specific NAMPT mutants. Cells stimulated with NAMPT 
mutated in the catalytic site failed to upregulate the mRNA expression of MCP1, RANTES and IL-6 (Fig. 
4D). These two sets of independent experiments suggest dependence of the proinflammatory action of 
exogenous NAMPT on its enzymatic activity. 
3.5 Inhibition of endogenous NAMPT magnifies chemokine expression 
Since cellular NAMPT was increased in tubular cells cultured in an inflammatory milieu and in tubular 
cells in vivo, we next explored whether endogenous NAMPT expressed in response to TNFα might 
regulate inflammation through its enzymatic activity. TNFα induction of MCP-1 mRNA in tubular cells 
peaks at 3h and later decreases towards baseline at 24h (Fig. 5A). When endogenous NAMPT activity 
was inhibited by FK866, TNFα proinflammatory effects were prolonged in time and increased MCP-1 
mRNA was still observed at 24h (Fig. 5A). Endogenous NAMPT inhibition also prolonged peak 
expression of RANTES, a gene whose expression in response to TNFα increases later and is more 
persistent than that of MCP-1[24](Fig. 5B). Endogenous NAMPT inhibition of cytokine-induced 
chemokine expression was confirmed when assessing secreted MCP-1 by ELISA. TNFα increased MCP-
1 secretion in tubular epithelial cells, and this increment was higher when endogenous NAMPT was 
inhibited (Fig. 5C). We next studied the effect of knocking down NAMPT expression by siRNA. siRNA-
mediated knock-down of NAMPT resulted in increased RANTES mRNA and a trend towards increased 
MCP-1 mRNA, both spontaneously and in the presence of TNFα (Fig. 5D,E). Thus, endogenous renal 
tubular cell NAMPT in response to TNFα appears to limit the proinflammatory action of TNFα. 
Furthermore, the spontaneous proinflammatory action of knocking down endogenous NAMPT suggests 
that part of the anti-inflammatory action of endogenous NAMPT may be enzyme activity-independent. In 
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conclusion, under the conditions explored endogenous and exogenous NAMPT have opposite effects on 
chemokine expression. 
3.5 Endogenous NAMPT may modulate cell death and tubular cell proliferation 
Since tubular cell apoptosis is a feature of DN[4], we next studied the modulation of apoptosis by 
endogenous tubular cell NAMPT by inhibiting its enzymatic activity. FK866 alone increased tubular cell 
proliferation after 24h (Fig. 6A), but did not modify the apoptotic rate at 24 or 48h in the absence of an 
inflammatory milieu (Fig. 6B). However, in an inflammatory microenvironment composed of TNF  and 
IFN  similar to what may be found in DN [9], the inhibition of endogenous NAMPT increased the 
apoptotic rate at 48h (Fig. 6C). Thus, the increase in endogenous NAMPT in response to an inflammatory 
milieu has an antiapoptotic action. 
3.6 Inhibition of endogenous NAMPT enhances TNF /IFN -induced expression of the lethal 
cytokine TRAIL 
We next addressed the relationship between proinflammatory cytokines, endogenous NAMPT and lethal 
cytokine expression. A proinflammatory milieu composed of TNF  and IFN  increased expression of 
TRAIL, the most upregulated lethal cytokine in DN, as previously observed by our group[10]. Inhibition 
of endogenous NAMPT enzymatic activity by FK866 did not modulate TRAIL expression by itself, but 
increased cytokine-induced TRAIL upregulation (Fig. 7). TRAIL had been previously shown to promote 
tubular cell death in an inflammatory milieu [10]. 
 
4 Discussion 
The main findings of our study are that NAMPT is upregulated by inflammatory mediators in human 
tubular cells and that endogenous NAMPT enzymatic activity plays a key role in protecting tubular cells 
from adverse consequence of an inflammatory environment such as cell death and a prolonged 
inflammatory response. This is consistent with the hypothesis that upregulation of endogenous NAMPT 
during kidney injury might be a compensatory protective mechanism that requires NAMPT enzymatic 
activity to protect from apoptosis and quench the inflammatory tubular cell response. This effect is in 
contrast to the previously described proinflammatory effect of exogenous NAMPT, that we have also 
observed and determined to be dependent on NAMPT enzymatic activity [31]. The involvement of the 
enzymatic activity is in line with a prior report in mesangial cells, where exogenous NAMPT actions on 
glucose transport were prevented by FK688 [21]. However, these observations differ from findings in 
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other organs, since in a lung carcinoma epithelial cell line NAMPT overexpression increased expression 
of inflammatory cytokines via a nonenzymatic mechanism [17]. Our experimental design differs from the 
latter in that we assessed the role of endogenous NAMPT following stimulation of its expression by a 
pathophysiologically relevant stimulus, as opposed to the enforced genetic-mediated expression of the 
gene. 
There are controversial results on NAMPT and diabetes, including the retraction of the initial report of its 
insulin mimetic activity [12]. Mice lacking NAMPT develop impaired glucose tolerance and defective 
insulin secretion, which are restored by administration of exogenous NAMPT [33]. NAMPT-mediated 
NAD biosynthesis regulates glucose homeostasis and maintenance of high circulating NMN levels by 
NAMPT is critical for normal β cell function [33]. However, NAMPT plasma levels have been reported 
increased, unchanged or decreased in diabetic patients [34-37] and are increased in CKD patients [38, 
39]. In experimental diabetes, plasma and renal NAMPT were elevated in type 2 diabetes rats with DN 
[22]. We have now confirmed increased tubular NAMPT in a type 1 diabetes DN model and provide 
evidence for a role of locally synthesized NAMPT in tissue protection in the presence of a cell 
environment that recapitulates the diabetic kidney injury milieu. This protective action of endogenous 
NAMPT, in the absence of enforced overexpression, differs from the proinflammatory role described up 
to now for exogenously added or for the enforced overexpression of NAMPT. 
Once demonstrated increased NAMPT in diabetic kidneys, the next step was to identify the factors 
responsible for this high expression. High glucose concentrations upregulate NAMPT synthesis in rat 
mesangial cells, murine podocytes and tubular cells [21, 22]. We also observed a trend toward increased 
NAMPT in human tubular cells exposed to a high glucose concentration, although the effect was milder 
than the one described in murine cells [22]. In contrast to the failure of angiotensin II to upregulate 
NAMPT in rat and murine renal cells [21, 22], we now report that TNFα upregulates NAMPT in human 
tubular cells. TNFα is upregulated in human and rat DN [9, 30]. Cytokines also upregulated expression of 
NAMPT in rheumatoid arthritis synovial fibroblasts [40]. Thus, inflammation, as metabolic stress does, 
upregulates NAMPT in tubular cells. However, the role of this stress-induced NAMPT upregulation in 
tubular cell biology had not been previously characterized. 
Initial attempts to unravel the role of NAMPT on cultured renal cells relied on the addition of exogenous 
NAMPT. Exogenous NAMPT induces production of profibrotic molecules in rat mesangial cells and 
murine podocytes and tubular epithelial cells [21, 22]. Exogenous NAMPT also increased MCP-1 
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expression in murine renal epithelial cells [22] and synthesis of several renin angiotensin system 
components in cultured rat mesangial cells [41]. Exogenous NAMPT increased the synthesis of pro-
fibrotic molecules and MCP-1 through a cytochalasin-B sensitive mechanism suggesting dependence on 
cellular glucose uptake [22]. These observations in kidney cells were consistent with data in other cell 
systems. Thus, NAMPT activated the transcription factors NF- B and AP1 and induced cytokine 
synthesis in rheumatoid arthritis synovial fibroblasts and monocytes. In fibroblasts NAMPT knockdown 
inhibited basal and TLR ligand-induced production of cytokines [40]. In contrast to the liver and the 
kidney, immune cells seem to rely exclusively on the NAMPT salvage pathway for NAD biosynthesis 
[42]. Thus, cells of the immune system express high levels of NAMPT [43]. In immune cells FK866 
decreased intracellular NAD and reduced TNF-α synthesis in response to LPS [43]. However, cells 
displaying low intracellular NAD levels retained the ability to secrete other proteins (such as the 
chemokine RANTES) in response to the same stimuli. Thus, the role of endogenous NAMPT on the 
synthesis of inflammatory mediators is cell-type specific: endogenous NAMPT may be required for full 
activation of the inflammatory response in cells with constitutive high NAMPT and NAD levels, such as 
immune cells. 
In cultured mesangial cells exogenous NAMPT increased intracellular NAD concentrations and FK866 
significantly inhibited NAMPT-induced NAD biosynthesis, suggesting NAMPT-mediated NAD 
biosynthesis [21]. In addition, in mesangial cells FK866 decreased exogenous NAMPT-induced glucose 
uptake, suggesting NAD involvement in NAMPT-mediated glucose uptake. However, the effect of 
FK866 on cell survival or inflammatory mediator synthesis was not explored. At least some actions of 
exogenous NAMPT on vascular cells depend on its enzymatic activity [31, 44, 45] and exogenous 
NAMPT enhanced vascular smooth muscle cell proliferation [19]. However, we observed that exogenous 
NAMPT did not modulate cell death or proliferation in non-stressed human tubular cells. 
Endogenous NAMPT may also regulate cell proliferation and cell death. In endothelial cells NAMPT 
overexpression increased proliferation and extended replicative lifespan, preferentially during glucose 
overload [46]. High intracellular NAD levels may act through sirtuins to favor tumor cell survival, 
especially in response to genotoxic stress [47]. Increased NAMPT activity is a physiological response to 
replenish NAD levels in cells exposed to stress. Thus, by blocking this response, FK866 decreased 
intracellular NAD and reduced proliferation and induced apoptosis in human leukemia cell lines [48] and 
inhibited growth of glioblastoma cells and other tumor cells [14, 49, 50]. This is the basis for a potential 
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role of NAMPT targeting on cancer therapy. Along the same lines, the NAMPT inhibitor FK866 
increased sensitivity to cell death of mouse fibroblasts exposed to genotoxic stress [13, 51], 
demonstrating that NAMPT regulation of cell viability requires its enzymatic activity and that 
endogenous NAMPT may be cytoprotective under conditions of cell stress. However there was no prior 
information on the relationship between the enzymatic function of stress-induced endogenous NAMPT 
and cell death or inflammatory responses in an inflammatory milieu, as may be found in the kidney 
during DN. In non-stressed tubular cells inhibition of NAMPT activity with FK866 slightly increased 
tubular cell proliferation, without modifying the apoptosis rate. This should be interpreted in the context 
of FK866 as an experimental anti-cancer drug. A potential extrapolation is that no direct kidney toxicity 
might be expected in normal healthy kidneys when using FK866 therapeutically for cancer. However, the 
consequences of the therapeutic use of FK866 for the kidney may differ under situations of kidney stress. 
Thus, tubular cells stressed with the inflammatory cytokines TNF  and IFN  became dependent on 
endogenous NAMPT for survival and inhibition of endogenous NAMPT activity increased cell death. 
The precise contributors to the increased cell death observed were not specifically characterized. 
However, increased expression of the lethal cytokine TRAIL was observed that coincided in time with the 
increased amount of cell death. TRAIL had been previously shown to promote death of tubular cells in an 
inflammatory environment [10].  Furthermore, under these culture conditions, inhibition of endogenous 
NAMPT prolonged TNF -induced chemokine expression to 24h. However, only a modest increase in 
total cell NAMPT was observed at this time point. This observation may have two potential explanations: 
a) that the trend to increased NAMPT observed at 24 h of stimulation is already functionally significant at 
24h or that the clearly increased endogenous extracellular NAMPT contributed to the effect; b) As an 
alternative, that another unidentified regulator might be responsible for the observation. 
 
5. Conclusion 
How do we reconcile the proinflammatory role of exogenous NAMPT with the anti-inflammatory, cell-
protective role of endogenous NAMPT in tubular cells in an inflammatory milieu? Any interpretation 
must take into account two facts: a) The concentration of exogenous NAMPT that promotes profibrotic 
and inflammatory responses in renal cells is in the 10-100 ng/ml range, as observed in this paper and by 
other authors [22]. This is the concentration range reported for circulating visfatin/NAMPT in CKD 
patients [38]. By contrast, extracellular NAMPT released by renal cells is measured in pg, a 1000-fold 
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lower concentration [21, 22]. We have now confirmed secretion of NAMPT by tubular cells, consistent 
with previous findings. Thus we are unable to pinpoint the protective effect of endogenous NAMPT to the 
fact that it is the intracellular form. We cannot discard that besides any difference in concentration; 
postraslational modifications of renal cell NAMPT explain these differential properties of endogenous 
NAMPT be it intracellular or secreted. b) The proinflammatory action of exogenous NAMPT has been 
observed in non-stressed cells, as exemplified by data presented here and by others [21, 22, 52] However, 
the anti-inflammatory and cell-protective endogenous NAMPT effects in tubular cells are observed when 
cells are stressed in an inflammatory microenvironment. Thus, our current interpretation is that low 
amounts of endogenous NAMPT synthesized by tubular cells in response to inflammatory stress help the 
cells to withstand that stress, while high amounts of exogenously added NAMPT may be detrimental, 
especially in the absence of stress. Our data and experimental design do not allow to discriminate between 
effects of endogenous, intracellular NAMPT versus endogenous extracellular (that is, NAMPT secreted 
by the tubular cells) NAMPT (Fig. 8). 
In summary, we have uncovered an anti-inflammatory, cell-protective role of endogenous NAMPT in 
tubular cells cultured under stress conditions with features of the DN milieu. This information will be 
useful to study NAMPT as a potential therapeutic target in kidney injury. In addition it raises a note of 
caution regarding the potential nephrotoxicity of the use of NAMPT inhibitors in other fields of 
Medicine, such as Oncology, when prescribed to patients with DN [53]. Taking into account the 
multifunctional nature of NAMPT, the final in vivo result of the therapeutic modulation of NAMPT on 
kidney injury has to be addressed in experimental animal models that discriminate between tubular and 
non-tubular sources of NAMPT, such as selective knock-down of NAMPT in tubular epithelium. 
 
Disclosure: The authors state no conflict of interests.
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Table 1. Rat weight gain and laboratory data at sacrifice.  
 
Mean  SEM of 6 animals per group. * p<0.05 vs control 
 
 
 
Weight gain  
(%) 
Systolic BP  
(mmHg) 
Glycemia  
(mg/dl) 
Urinary albumin 
(mg/24h) 
Control 76 ±18 112 ± 4 126 ± 2 0.44 ± 0.3 
DN 61 ± 25 121 ± 5 * 383 ± 135* 2.31 ± 0.4* 
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Legends to figures 
  
Figure 1. Kidney NAMPT expression is increased in rats with type 1 diabetes. A) Whole kidney 
NAMPT protein is increased in rat experimental DN assessed by Western blot. β-actin was used as 
loading control. B) Kidney NAMPT mRNA levels are significantly increased in rat DN. Values for 
mRNA were normalized to the housekeeping gene 18s expression. C) NAMPT immunohistochemistry in 
renal cortex. Quantification and representative image. D) NAMPT immunohistochemistry in renal 
medulla. Representative image and quantification. Magnification 20X. Neg. con.: negative control for the 
technique. *p<0.05 vs control. Mean + S.E.M. of 6 animals.  
 
Figure 2. TNFα increases NAMPT expression and activity in cultured human tubular cells. A) 
NAMPT mRNA expression measured by real time RT-PCR. Cells were stimulated with 50 ng/ml TNFα  
in normal glucose (5 mM) or high glucose (25 mM) culture medium for 3 and 24 hours. Ribosomal 18S 
was used as housekeeping gene for normalization. *p<0.05 vs control. B) 50 ng/ml TNFα for 48 hours 
increased whole cell NAMPT protein as detected by Western blot. β-Actin was used as loading control. 
Mannitol was added to normal glucose culture medium to control for osmolarity changes. Mean + S.E.M 
of 3 independent experiments. * p<0.05 vs control. C) NAMPT enzymatic activity measured by a 
NAD/NADH kit. The amount of NAD+ was higher in HK2 cells stimulated with 50 ng/mL of TNFα for 
24 h. This increase was inhibited by the preincubation with the NAMPT enzymatic activity inhibitor 
FK866. * p<0.05 vs. Control, # p<0.05 vs. TNFα. All experiments are Mean + S.E.M of at least 3 
independent experiments. 
 
Figure 3. Exogenous NAMPT does not modulate tubular epithelial cell proliferation or death. 
Exogenous NAMPT stimulation of HK-2 cells at different concentrations for 24 hours does not change 
cell viability assessed by MTS-PMS assay (A) nor apoptosis (B) or proliferation (C) measured by flow 
cytometry analysis of DNA content. 
 
Figure 4. Inhibition of NAMPT enzymatic activity prevents exogenous NAMPT proinflammatory 
effects in tubular cells. A) Exogenous NAMPT increased in a dose-dependent manner chemokine MCP-
1 mRNA expression measured by real-time PCR at 24h. Mean ± S.E.M. of 3 independent experiments. 
 19 
*p<0.05 vs control. B and C) Tubular cells were incubated with 10 nM FK866 before stimulation with 
exogenous 100 ng/ml NAMPT for 24 hours. MCP-1 (B) and RANTES (C) gene expression were 
evaluated by real time RT-PCR. * p<0.05 vs eNAMPT. Mean+S.E.M. of 3 independent experiments. D) 
Tubular cells were stimulated with 100 ng/ml wild-type NAMPT or enzymatically impaired NAMPT 
mutants (R392A, S200D, H247E) for 24h. RNA expression for RANTES, MCP-1 and IL-6 was assessed 
by real time RT-PCR. Mean+S.E.M. of 3 independent experiments. 
 
Figure 5. Inhibition of endogenous NAMPT enzymatic activity magnifies TNFα-induced 
upregulation of chemokines expression. Time-course of MCP-1 (A) and RANTES (B) mRNA 
expression induced by 50 ng/ml TNFα in tubular cells assessed by real time RT-PCR. Some cells were 
prestimulated with 10 nM FK866 before adding TNFα. *p <0.05 vs TNFα alone. Results expressed as 
mean+S.E.M of 3 independent experiments. C) Secreted MCP-1 was measured by ELISA in HK2 cell 
supernatants. TNFα for 24 h. increased MCP-1 release. Preincubation with the NAMPT inhibitor FK866 
resulted in a higher increase in MCP-1 secretion. * p<0.05 vs. control, # p<0.05 vs. TNFα. D, E) Tubular 
epithelial cells were transfected with scramble or NAMPT siRNA for 24 hours, and then 50 ng/ml TNFα 
were added for 24h. MCP-1 (D) and RANTES (E) mRNA were assessed by real time RT-PCR. Results 
expressed as mean+S.E.M of 3 independent experiments * p<0.03 vs control. 
 
Figure 6. Inhibition of endogenous NAMPT enzymatic activity promotes tubular cell apoptosis in 
an inflammatory milieu. A) The NAMPT inhibitor FK866 increased the proliferation rate in proximal 
tubular cells cultured in glucose 11 mM. B) However, FK866 alone did not influence apoptosis. Both 
processes were assessed by flow cytometry analysis of DNA content. *p<0.05 vs control. Mean+S.E.M. 
of 3 independent experiments. C) The pro-apoptotic effect of TNFα/IFNγ (50 ng/ml and 5 ng/ml) in a 
high glucose milieu (25 mM) was increased when NAMPT enzymatic activity was inhibited with 10 nM 
FK866 for 48 hours. *p<0.05 vs TNFα/IFNγ. Mean+S.E.M. of 3 independent experiments. 
 
Figure 7. Inhibition of endogenous NAMPT further increases TNFα/IFNγ-induced TRAIL lethal 
cytokine expression. Cells were cultured for 24h with TNFα/IFNγ (50 ng/ml and 5 ng/ml). NAMPT 
enzymatic activity was inhibited with 10 nM FK866. Western blot of cell lysates. β-Actin was used as 
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loading control. Results expressed as mean+S.E.M of 4 independent experiments. Representative Western 
blot. * p<0.05 vs TNFα/IFNγ alone. 
 
Figure 8. Hypothetical role of exogenous and endogenous NAMPT on kidney tubular epithelial cell 
pathophysiology. During kidney injury tubular cell NAMPT is increased. In addition, kidney cells may 
be exposed to exogenous NAMPT, not originated in tubular cells, that  may be derived from the 
circulation where both the liver and fat tissue are thought to be contributors, or may be released locally 
from macrophages. This manuscript confirms the proinflammatory action of exogenous, extracellular 
NAMPT over parenchymal cells described in previous publications. In addition it provides evidence that 
cultured tubular cells express increased amounts of endogenous NAMPT that can be found both as an 
extracellular protein in the cell culture supernatants and as an intracellular protein in cell extracts. 
Evidence derived from siRNA targeting of endogenous NAMPT and from pharmacological inhibition of 
endogenous NAMPT enzymatic activity suggests an anti-inflammatory, cell-protective role for 
endogenous NAMPT. The design of the experiments does not allow to independently explore the role of 
extracellular versus intracellular endogenous NAMPT. The relative contribution of both sources of 
NAMPT should be addressed in vivo, for example, by selectively knocking down NAMPT in tubular 
epithelium, Potential explanations for the diverse roles of endogenous vs exogenous NAMPT include: a) 
a key contribution of intracellular NAMPT to the observed protection by endogenous NAMPT; b) a 
potential protective role of different molecular forms of extracellular NAMPT produced by tubular cells; 
and c) a hypothetical role for the concentration of extracellular NAMPT. In this regard, NAMPT 
concentrations in renal cell supernatants have been reported to be low. The anti-inflammatory and cell-
protective endogenous NAMPT effects in tubular cells are most marked when cells are stressed in an 
inflammatory microenvironment. Thus, intracellular NAMPT or low amounts of (modified?) endogenous 
NAMPT released by tubular cells in response to inflammatory stress may help the cells to withstand that 
stress, while high amounts of exogenously added extracellular NAMPT may be detrimental, especially in 
the absence of stress. 
 
 
Con formato: Resaltar
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Supplementary figure 1. Tubular epithelial cells secrete NAMPT. Cells were stimulated with TNFα 
(50ng/ml), and then supernatants were collected after 24 and 48h. Representative SDS-PAGE 
microphotography. 40 ug supernatants were loaded per well.  
